Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Catalyst Pharmaceuticals, Inc.
CPRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8B
$31.45
▲ +0.03%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$19.05 - $32.56
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 46.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Orphan drug designations providing market exclusivity and extended patent protection
- First-mover advantage in LEMS treatment with established Firdapse market presence
- Specialized focus on rare neuromuscular diseases with limited competitive alternatives
- Strategic partnerships with major pharmaceutical companies validating product pipeline
- Pediatric formulation (Ruzurgi) addressing underserved pediatric rare disease market
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Steady revenue growth (20% YoY)
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Hot
+27.3% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CPRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 11, 2026
Reported EPS of $0.52 vs $0.64 consensus (-18.8% surprise). Revenue of $149.3M vs $149.5M expected (-0.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-18.8%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
+28%
+44%
+19%
+15%
+8%
+6%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$122.7M
$128.7M
$141.8M
$141.4M
$146.6M
$148.4M
$152.6M
$149.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
42.7%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
$31.75
▲ +1.0% vs $31.45
Latest: HC Wainwright · $31.50 · May 28, 2026
2 analysts covering